Oct 07, 2022 15:00 JST

Source: Olympus

Olympus EU-ME3 Ultrasound Processor, Delivers Higher Resolution Images for Endoscopic Ultrasound
~ Supporting More Accurate Diagnosis and Treatment of Pancreaticobiliary and Lung Disease ~

- EU-ME3 at United European Gastroenterology Week (UEG Week 2022) October 8 to 11 -

TOKYO / HAMBURG, Oct 07, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of EU-ME3, a new Endoscopic Ultrasound Processor*, which addresses the needs of healthcare professionals for high-quality clear images when conducting the endoscopic ultrasound procedure. EU-ME3 will be launched in Europe, the Middle East, Africa, parts of Asia, and Oceania within this fiscal year.

Olympus announces the global launch of the EVIS EUS / EU-ME3 Endoscopic Ultrasound Center. [Image: Olympus Corp]
 


Olympus, a pioneer in endoscopic ultrasound (EUS) technology, aims to leverage its expertise to enhance the care pathway in gastrointestinal and respiratory disease management. The technology is used for endoscopic ultrasonography, imaging to support the diagnosis of lesions in the pancreas, the bile ducts, or lesions that are located deep inside the body and are not visible with gastrointestinal endoscopes. In addition, it enables the detailed examination of pancreatitis, pancreatic cancer, and the diagnosis of cancer invasion in the stomach and the esophagus. Endoscopic ultrasound also plays a key role in facilitating the visualization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for early, minimally invasive diagnosis and lung cancer staging.

"It is said that pancreatic cancer is difficult to be detected in its early stages, and that lung cancer has the highest mortality rate among all cancers. With the launch of the EU-ME3, Olympus aims to enhance the standard of care including these diseases and to further improve the quality of life of patients," said Hironobu Kawano, Head of Endoscopic Solutions Division at Olympus.

- Advancing the dimensions of endosonography

With the needs of healthcare professionals and patient outcomes at its core, EU-ME3 is tailored to improve a variety of procedures.

- Enhanced visualization and usability

EU-ME3 provides outstanding image quality and functionality. The image quality has been substantially enhanced compared to the prior generation model (EU-ME2), providing enhanced visualization, therefore supporting a more reliable diagnosis and treatment.

Shear Wave Quantification, a newly equipped feature for EU-ME3, also contributes to accurate diagnosis by providing quantitative information on the stiffness of tumor and inflamed lesions, which is an important factor when diagnosing the degree of pancreatitis and malignancy of pancreatic cancer during endoscopic ultrasonography.

- Focus on procedure, with tailored technology

The Endoscopic ultrasound procedure typically utilizes a variety of observation modes dependent on procedure type or clinical area. Subsequently, in addition to the basic observation mode, EU-ME3 offers multiple software options for individual clinical needs, aiming to stay flexible in the selection of functions and tailor EU-ME3 depending on specialty.

Smart and customizable user settings make it easy to fulfil needs for multiple specialties and personal requirements. The backlit keyboard includes a simple, easy-to-use large touch panel and trackpad, designed to support better operability and easier cleaning.

With EU-ME3, the aim is to provide seamless workflow integration for healthcare professionals while advancing the dimensions of Endosonography for better overall patient outcome.

About Olympus

In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world's first gastrocamera in 1950, Olympus' Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, digital and integrated customer solutions, as well as solutions for infection prevention. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

Media Contacts
Nao Tsukamoto - Global-Public_Relations@olympus.com
Jessica Lee - Jessica.yy.lee@fleishman.com

* Registered name: EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME3. EU-ME3 is manufactured by Olympus Medical Systems Corporation.
* Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLY] https://www.olympus-global.com

Source: Olympus
Sectors: BioTech, Healthcare & Pharm, MedTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
November 19 2024 14:30 JST
 
Olympus Launches VISERA S, a New Imaging Platform
September 30 2024 14:00 JST
 
Olympus Launches New 4K Camera Head for Urological Endoscopy
September 20 2024 14:00 JST
 
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India
June 12 2024 10:00 JST
 
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
March 27 2024 14:00 JST
 
Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
January 24 2024 14:00 JST
 
Olympus Named to Dow Jones Sustainability World Index for Three Consecutive Years
December 11 2023 10:00 JST
 
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
December 07 2023 10:00 JST
 
Olympus's Net-Zero Targets Approved by SBTi
November 30 2023 10:00 JST
 
Olympus Names Dr. John de Csepel as Chief Medical Officer
October 06 2023 20:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>